User login
CAR T Therapy: From Bench to Bedside and Back
Release Date: July 15, 2018
Expiration Date: July 14, 2019
Note: This activity is no longer available for credit
Introductory Comments: (Duration: 9 minutes)
Aaron P. Rapoport, MD
Bone Marrow Transplant Program
University of Maryland School of Medicine
Baltimore, MD
Presentation: (Duration: 39 minutes)
Carl H. June, MD
Richard W. Vague Professor in Immunotherapy
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Provided by:
Learning Objectives
• Review clinical data and individual case studies to determine where CAR T-cell therapy might be appropriate in the treatment of adult and pediatric patients with leukemia, lymphoma, and multiple myeloma.
• Discuss the management of cytotoxicity of CAR T-cell therapy.
Target Audience
Hematologists, oncologists, and other members of the healthcare team who treat or manage patients with hematologic malignancies.
Statement of Need
It is critical that clinicians managing patients with acute leukemia and other hematologic malignancies are cognizant of exciting breakthroughs and are also able to integrate recent progress into practice. However, given the overwhelming influx of data, it is no surprise that many hematology professionals face difficulties in identifying the most relevant findings for clinical practice. Hematologists are unable to stay abreast of the latest evidence on investigational agents. Educational programs are thus crucial to address this important professional practice gap.
Faculty
Carl H. June, MD
Richard W. Vague Professor in Immunotherapy
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Disclosures: Consultant: Novartis; Grant/Research support and royalties/IPR: Novartis
Stockholder: Tmunity Therapeutics, Inc.
Aaron P. Rapoport, MD
Bone Marrow Transplant Program
University of Maryland School of Medicine
Baltimore, Maryland
Disclosures: No relevant financial relationships with a commercial supporter
Permissions
- Slide 3: Complex tumor, host and environmental factors govern the strength and timing of anti-cancer immune responses
- Reprinted from Immunity, Vol 39/No 1, Chen DS, Mellman I, Oncology meets immunology: the cancer-immunity cycle, pp 1-10, 2013, with permission from Elsevier
- Slide 9: Genes differentially expressed in CART19 cellular infusion products from CLL patients
- From Fraietta JA, Lacey SF, Orlando EJ, . . . June CH, Melenhorst JJ. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 2018; 24:563-571
- Slide 10: Characterization of CLL CAR T cells in NSG CLL model
- Same as slide 9
- Slide 15: First adult ALL patient
- Photos originally published in Kaiser Health News/Photo courtesy of Dr Keith Eaton. Available at: https://khn.org/news/cascade-of-costs-could-push-new-gene-therapy-above-1-million-per-patient/
- Slide 21: Efficient trafficking of CTL019 T Cells to CNS in ALL
- From N Engl J Med, Grupp SA, Kalos M, Barrett D, . . V. June CH, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, Volume No 368, pp 1509-1518. Copyright © 2013 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
- Slide 26: Long-term persistence and expression of CTL019 is associated with durable remission in leukemia: Predictive Biomarker
- From Porter DL, Hwang WT, Frey NV . . . June CH. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015; 7(303):303ra139. Reprinted with permission from AAAS.
- Slide 28: Rapid massive expansion of clonal CART cell population in patient #10
- Initially published in Fraietta JA, Nobles CL, Sammons MA, . . . June CH, Melenhors JJ. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 2018; 558(7709):307-312
- Slide 29: Mapping CAR integration site in Pt #10
- Same as slide 28.
- Slide 31: Long-term stable persistence of TET2-deficient CAR T cells in Pt #10
- Same as slide 28
- Slide 32: Epigenetic and genetic changes uncovered by ATAC-seq in Pt #10
- Same as slide 28.
- Slide 33: TET2 knock down in healthy donor T cells
- Same as slide 28.
- Slide 34: TET2 knock down in healthy donor T cells
- Same as slide 28.
- Slide 36: CAR T for myeloma: BCMA
- From Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev 2011; 244(1):115-33. Reprinted with permission from John Wiley and Sons.
- Slide 38: CAR T for myeloma: Patient #1
- Photo originally published by UT Southwestern Medical Center. Available at: https://www.utsouthwestern.edu/newsroom/articles/year-2018/wright-car-t.html
- Slide 39: Autoimmunity is the “Achilles’ Heel” of immunotherapy
- First published in June CH, Warshauer JT, and Bluestone JA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med 2017;23(5):540-7
- Slide 41: Multiplex CRISPR /Cas9 editing: Universal T cells TCR, HLA, PD-1, CTLA-4 and Fas
- From Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, Zhao Y. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget 2017; 8:17002-17011.
- Slide 45: CAR T-cell trials for cancer are now global
- From June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science 2018; 359:1361-1365. Reprinted with permission from AAAS.
Disclaimer
The content and views presented in this educational activity are those of the author and do not necessarily reflect those of Hemedicus or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Release Date: July 15, 2018
Expiration Date: July 14, 2019
Note: This activity is no longer available for credit
Introductory Comments: (Duration: 9 minutes)
Aaron P. Rapoport, MD
Bone Marrow Transplant Program
University of Maryland School of Medicine
Baltimore, MD
Presentation: (Duration: 39 minutes)
Carl H. June, MD
Richard W. Vague Professor in Immunotherapy
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Provided by:
Learning Objectives
• Review clinical data and individual case studies to determine where CAR T-cell therapy might be appropriate in the treatment of adult and pediatric patients with leukemia, lymphoma, and multiple myeloma.
• Discuss the management of cytotoxicity of CAR T-cell therapy.
Target Audience
Hematologists, oncologists, and other members of the healthcare team who treat or manage patients with hematologic malignancies.
Statement of Need
It is critical that clinicians managing patients with acute leukemia and other hematologic malignancies are cognizant of exciting breakthroughs and are also able to integrate recent progress into practice. However, given the overwhelming influx of data, it is no surprise that many hematology professionals face difficulties in identifying the most relevant findings for clinical practice. Hematologists are unable to stay abreast of the latest evidence on investigational agents. Educational programs are thus crucial to address this important professional practice gap.
Faculty
Carl H. June, MD
Richard W. Vague Professor in Immunotherapy
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Disclosures: Consultant: Novartis; Grant/Research support and royalties/IPR: Novartis
Stockholder: Tmunity Therapeutics, Inc.
Aaron P. Rapoport, MD
Bone Marrow Transplant Program
University of Maryland School of Medicine
Baltimore, Maryland
Disclosures: No relevant financial relationships with a commercial supporter
Permissions
- Slide 3: Complex tumor, host and environmental factors govern the strength and timing of anti-cancer immune responses
- Reprinted from Immunity, Vol 39/No 1, Chen DS, Mellman I, Oncology meets immunology: the cancer-immunity cycle, pp 1-10, 2013, with permission from Elsevier
- Slide 9: Genes differentially expressed in CART19 cellular infusion products from CLL patients
- From Fraietta JA, Lacey SF, Orlando EJ, . . . June CH, Melenhorst JJ. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 2018; 24:563-571
- Slide 10: Characterization of CLL CAR T cells in NSG CLL model
- Same as slide 9
- Slide 15: First adult ALL patient
- Photos originally published in Kaiser Health News/Photo courtesy of Dr Keith Eaton. Available at: https://khn.org/news/cascade-of-costs-could-push-new-gene-therapy-above-1-million-per-patient/
- Slide 21: Efficient trafficking of CTL019 T Cells to CNS in ALL
- From N Engl J Med, Grupp SA, Kalos M, Barrett D, . . V. June CH, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, Volume No 368, pp 1509-1518. Copyright © 2013 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
- Slide 26: Long-term persistence and expression of CTL019 is associated with durable remission in leukemia: Predictive Biomarker
- From Porter DL, Hwang WT, Frey NV . . . June CH. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015; 7(303):303ra139. Reprinted with permission from AAAS.
- Slide 28: Rapid massive expansion of clonal CART cell population in patient #10
- Initially published in Fraietta JA, Nobles CL, Sammons MA, . . . June CH, Melenhors JJ. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 2018; 558(7709):307-312
- Slide 29: Mapping CAR integration site in Pt #10
- Same as slide 28.
- Slide 31: Long-term stable persistence of TET2-deficient CAR T cells in Pt #10
- Same as slide 28
- Slide 32: Epigenetic and genetic changes uncovered by ATAC-seq in Pt #10
- Same as slide 28.
- Slide 33: TET2 knock down in healthy donor T cells
- Same as slide 28.
- Slide 34: TET2 knock down in healthy donor T cells
- Same as slide 28.
- Slide 36: CAR T for myeloma: BCMA
- From Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev 2011; 244(1):115-33. Reprinted with permission from John Wiley and Sons.
- Slide 38: CAR T for myeloma: Patient #1
- Photo originally published by UT Southwestern Medical Center. Available at: https://www.utsouthwestern.edu/newsroom/articles/year-2018/wright-car-t.html
- Slide 39: Autoimmunity is the “Achilles’ Heel” of immunotherapy
- First published in June CH, Warshauer JT, and Bluestone JA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med 2017;23(5):540-7
- Slide 41: Multiplex CRISPR /Cas9 editing: Universal T cells TCR, HLA, PD-1, CTLA-4 and Fas
- From Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, Zhao Y. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget 2017; 8:17002-17011.
- Slide 45: CAR T-cell trials for cancer are now global
- From June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science 2018; 359:1361-1365. Reprinted with permission from AAAS.
Disclaimer
The content and views presented in this educational activity are those of the author and do not necessarily reflect those of Hemedicus or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Release Date: July 15, 2018
Expiration Date: July 14, 2019
Note: This activity is no longer available for credit
Introductory Comments: (Duration: 9 minutes)
Aaron P. Rapoport, MD
Bone Marrow Transplant Program
University of Maryland School of Medicine
Baltimore, MD
Presentation: (Duration: 39 minutes)
Carl H. June, MD
Richard W. Vague Professor in Immunotherapy
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Provided by:
Learning Objectives
• Review clinical data and individual case studies to determine where CAR T-cell therapy might be appropriate in the treatment of adult and pediatric patients with leukemia, lymphoma, and multiple myeloma.
• Discuss the management of cytotoxicity of CAR T-cell therapy.
Target Audience
Hematologists, oncologists, and other members of the healthcare team who treat or manage patients with hematologic malignancies.
Statement of Need
It is critical that clinicians managing patients with acute leukemia and other hematologic malignancies are cognizant of exciting breakthroughs and are also able to integrate recent progress into practice. However, given the overwhelming influx of data, it is no surprise that many hematology professionals face difficulties in identifying the most relevant findings for clinical practice. Hematologists are unable to stay abreast of the latest evidence on investigational agents. Educational programs are thus crucial to address this important professional practice gap.
Faculty
Carl H. June, MD
Richard W. Vague Professor in Immunotherapy
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Disclosures: Consultant: Novartis; Grant/Research support and royalties/IPR: Novartis
Stockholder: Tmunity Therapeutics, Inc.
Aaron P. Rapoport, MD
Bone Marrow Transplant Program
University of Maryland School of Medicine
Baltimore, Maryland
Disclosures: No relevant financial relationships with a commercial supporter
Permissions
- Slide 3: Complex tumor, host and environmental factors govern the strength and timing of anti-cancer immune responses
- Reprinted from Immunity, Vol 39/No 1, Chen DS, Mellman I, Oncology meets immunology: the cancer-immunity cycle, pp 1-10, 2013, with permission from Elsevier
- Slide 9: Genes differentially expressed in CART19 cellular infusion products from CLL patients
- From Fraietta JA, Lacey SF, Orlando EJ, . . . June CH, Melenhorst JJ. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 2018; 24:563-571
- Slide 10: Characterization of CLL CAR T cells in NSG CLL model
- Same as slide 9
- Slide 15: First adult ALL patient
- Photos originally published in Kaiser Health News/Photo courtesy of Dr Keith Eaton. Available at: https://khn.org/news/cascade-of-costs-could-push-new-gene-therapy-above-1-million-per-patient/
- Slide 21: Efficient trafficking of CTL019 T Cells to CNS in ALL
- From N Engl J Med, Grupp SA, Kalos M, Barrett D, . . V. June CH, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, Volume No 368, pp 1509-1518. Copyright © 2013 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
- Slide 26: Long-term persistence and expression of CTL019 is associated with durable remission in leukemia: Predictive Biomarker
- From Porter DL, Hwang WT, Frey NV . . . June CH. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015; 7(303):303ra139. Reprinted with permission from AAAS.
- Slide 28: Rapid massive expansion of clonal CART cell population in patient #10
- Initially published in Fraietta JA, Nobles CL, Sammons MA, . . . June CH, Melenhors JJ. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 2018; 558(7709):307-312
- Slide 29: Mapping CAR integration site in Pt #10
- Same as slide 28.
- Slide 31: Long-term stable persistence of TET2-deficient CAR T cells in Pt #10
- Same as slide 28
- Slide 32: Epigenetic and genetic changes uncovered by ATAC-seq in Pt #10
- Same as slide 28.
- Slide 33: TET2 knock down in healthy donor T cells
- Same as slide 28.
- Slide 34: TET2 knock down in healthy donor T cells
- Same as slide 28.
- Slide 36: CAR T for myeloma: BCMA
- From Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev 2011; 244(1):115-33. Reprinted with permission from John Wiley and Sons.
- Slide 38: CAR T for myeloma: Patient #1
- Photo originally published by UT Southwestern Medical Center. Available at: https://www.utsouthwestern.edu/newsroom/articles/year-2018/wright-car-t.html
- Slide 39: Autoimmunity is the “Achilles’ Heel” of immunotherapy
- First published in June CH, Warshauer JT, and Bluestone JA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med 2017;23(5):540-7
- Slide 41: Multiplex CRISPR /Cas9 editing: Universal T cells TCR, HLA, PD-1, CTLA-4 and Fas
- From Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, Zhao Y. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget 2017; 8:17002-17011.
- Slide 45: CAR T-cell trials for cancer are now global
- From June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science 2018; 359:1361-1365. Reprinted with permission from AAAS.
Disclaimer
The content and views presented in this educational activity are those of the author and do not necessarily reflect those of Hemedicus or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
The Long and Winding Road: PTCL 10 Years from Now
Release Date: March 20, 2018
Expiration Date: March 19, 2019
Note: This activity is no longer available for credit
Agenda
New targeted agents for PTCL
(Duration: 20 minutes)
Pier Luigi Zinzani, MD, PhD
Bologna University
Institute of Hematology “Seragnoli”
Bologna, Italy
Recently approved therapies for PTCL in Asia:
What have we learned from the US experience?
(Duration: 18 minutes)
Won Seog Kim, MD, PhD
Samsung Medical Center
Seoul, Republic of Korea
Novel combination therapies:
Where are we now and where are we going?
(Duration: 23 minutes)
Owen A. O’Connor, MD, PhD
Columbia University Medical Center
The New York Presbyterian Hospital
New York, NY USA
Provided by:
Original activity supported by an educational grant from:
Spectrum Pharmaceuticals
Learning Objectives
At the conclusion of this educational activity, the healthcare team will be better able to:
- Discuss the treatment and management of peripheral T-cell lymphoma
- Appraise how U.S. T-cell lymphoma treatment experience can impact practice in Asia
- Summarize the importance of combination therapy in peripheral T-cell lymphoma
Target Audience
Hematologists, oncologists, and other clinicians and scientists with an interest in T-cell lymphoma
Statement of Need
Peripheral T-cell lymphomas (PTCL) are rare, heterogeneous and aggressive neoplasms that are associated with a poor prognosis. In addition, with current therapies, up to 70% of patients undergo relapse or develop refractory disease. Recent evidence has indicated an increase in the incidence of PTCLs and hence current challenges including pathobiology, clinical management, new drug testing as well as clinical trial accrual, need to be addressed. This activity will provide the healthcare team with the ideal foundation to facilitate progress in PTCL treatment and management.
Won Seog Kim, MD, PhD (Presenter)
Samsung Medical Center
Seoul, Republic of Korea
Disclosure: Consulting fees: Celltrion; Contracted research: Takeda; Kyowa-Kirin; J & J; Merck; Donga; Novartis; Celltrion
Owen A. O’Connor, MD, PhD (Presenter)
Columbia University Medical Center
The New York Presbyterian Hospital
New York, NY USA
Disclosure: Contracted research: Celgene; Merck; Spectrum; Agensys
Pier Luigi Zinzani, MD, PhD (Presenter)
Bologna University
Institute of Hematology “Seragnoli”
Bologna, Italy
Disclosure: Speakers Bureau: Janssen; Merck; Servier; Gilead; Verastem; BMS; Sandoz; Mundipharma
Permissions
Won Seog Kim presentation
Slide 4: Frequency of T and NK-cell lymphomas in Asia
Park S, Ko YH. Peripheral T cell lymphoma in Asia. Int J Hematol 2014;99:227-239. Reprinted with permission of the Japanese Society of Hematology.
Slide 29: Off-label use: 100mg of pembrolizumab, HK, Singapore, Korea
Republished with permission of the American Society of Hematology, from Kwong YL, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase. Blood. 2017;129(17):2437-2442; permission conveyed through Copyright Clearance Center, Inc.
Owen A. O’Connor presentation
Slide 12: Schematic of study design, patient disposition, and thrombocytopenia as a function of schedule & dose
Republished with permission of American Society of Hematology, from Amengual JE…O’Connor OA. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood 2018;131:397-407; permission conveyed through Copyright Clearance Center, Inc.
Slide 13: Summary of response rates across study population for patients treated with romidepsin and pralatrexate
Same as slide above.
Slide 14: Pharmacokinetic parameters for pralatrexate and romidepsin in the study population
Same as slide above.
Slide 15: PFS and OS as a function of treatment in study population
Same as slide above.
Slide 19: The combination of HoME and HDAC inhibitor synergistically produces apoptosis across panel of T-cell lymphomas: tCTCL H9
Marchi E . . . O’Connor OA.The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. Br J Haematol 2015; 171:215-226.
Slide 20: Supervised hierarchial clustering based on GEP
Same as slide above.
Slide 27: Panobinostat plus bortezomib in PTCL
Reprinted from Lancet Haematol, Tan D, et al. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. 2015; 2(8):e326-e333, with permission from Elsevier.
Pier Luigi Zinzani presentation
Slides 4, 11: New agents in T-cell lymphomas (2), Belinostat (2)
O’Connor OA, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 2015; 33: 2492-2499. Reprinted with permission. © 2015 American Society of Clinical Oncology. All rights reserved.
Slides 5, 8, 10, 12, 18, 20: Pralatrexate (1), Romidepsin (1), Belinostat (1), Brentuximab vedotin – Anaplastic large cell lymphoma (1), Brentuximab vedotin – CD30+ peripheral T-cell lymphoma (1), Off-label compounds in peripheral T-cell lymphomas
Reprinted from Cancer Treat Rev, volume 60, Broccoli A, Argnani L, Zinzani PL. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease, pp 120-129, © 2017, with permission from Elsevier.
Slides 6, 7: Pralatrexate (2) and Pralatrexate (3)
O’Connor OA, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol, 2011; 29: 1182-1189. Reprinted with permission. © 2011 American Society of Clinical Oncology. All rights reserved.
Slide 9: Romidepsin (2)
Coiffier B, et al. J Clin Oncol 2012; 30: 631-636. Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
Slides 13, 14: Brentuximab vedotin – Anaplastic large cell lymphoma (2), Brentulximab vedotin — Anaplastic large cell lymphoma (3)
Pro B, et al. J Clin Oncol 2012; 30: 2190-2196. Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
Slides 16, 17: Brentuximab vedotin – Anaplastic large cell lymphoma (5), Brentuximab vedotin – Anaplastic large cell lymphoma (6)
Broccoli A, et al. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica 2017; 102: 1931-1935. Obtained from the Haematologica Journal website http://www.haematologica.org
Slide 19: Brentuximab vedotin –CD30+ peripheral T-cell lymphomas (2)
Horwitz SM, et al. Blood 2014; 123: 3095-3100. Permission conveyed through Copyright Clearance Center, Inc.
Slide 21: Gemcitabine in peripheral T-cell lymphomas
Zinzani PL, et al. Ann Oncol 2010; 21: 860-863. European Society of Medical Oncology licensee.
Slide 23: Lenalidomide in T-cell lymphomas (2)
Reprinted from Morschhauser F, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 2013, with permission from Elsevier.
Slides 24, 25: Bendamustine in T-cell lymphomas (1), Bendamustine in T-cell lymphomas (2)
Damaj G, et al. J Clin Oncol 2012; 31: 104-110. Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Hemedicus, the supporter, or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Release Date: March 20, 2018
Expiration Date: March 19, 2019
Note: This activity is no longer available for credit
Agenda
New targeted agents for PTCL
(Duration: 20 minutes)
Pier Luigi Zinzani, MD, PhD
Bologna University
Institute of Hematology “Seragnoli”
Bologna, Italy
Recently approved therapies for PTCL in Asia:
What have we learned from the US experience?
(Duration: 18 minutes)
Won Seog Kim, MD, PhD
Samsung Medical Center
Seoul, Republic of Korea
Novel combination therapies:
Where are we now and where are we going?
(Duration: 23 minutes)
Owen A. O’Connor, MD, PhD
Columbia University Medical Center
The New York Presbyterian Hospital
New York, NY USA
Provided by:
Original activity supported by an educational grant from:
Spectrum Pharmaceuticals
Learning Objectives
At the conclusion of this educational activity, the healthcare team will be better able to:
- Discuss the treatment and management of peripheral T-cell lymphoma
- Appraise how U.S. T-cell lymphoma treatment experience can impact practice in Asia
- Summarize the importance of combination therapy in peripheral T-cell lymphoma
Target Audience
Hematologists, oncologists, and other clinicians and scientists with an interest in T-cell lymphoma
Statement of Need
Peripheral T-cell lymphomas (PTCL) are rare, heterogeneous and aggressive neoplasms that are associated with a poor prognosis. In addition, with current therapies, up to 70% of patients undergo relapse or develop refractory disease. Recent evidence has indicated an increase in the incidence of PTCLs and hence current challenges including pathobiology, clinical management, new drug testing as well as clinical trial accrual, need to be addressed. This activity will provide the healthcare team with the ideal foundation to facilitate progress in PTCL treatment and management.
Won Seog Kim, MD, PhD (Presenter)
Samsung Medical Center
Seoul, Republic of Korea
Disclosure: Consulting fees: Celltrion; Contracted research: Takeda; Kyowa-Kirin; J & J; Merck; Donga; Novartis; Celltrion
Owen A. O’Connor, MD, PhD (Presenter)
Columbia University Medical Center
The New York Presbyterian Hospital
New York, NY USA
Disclosure: Contracted research: Celgene; Merck; Spectrum; Agensys
Pier Luigi Zinzani, MD, PhD (Presenter)
Bologna University
Institute of Hematology “Seragnoli”
Bologna, Italy
Disclosure: Speakers Bureau: Janssen; Merck; Servier; Gilead; Verastem; BMS; Sandoz; Mundipharma
Permissions
Won Seog Kim presentation
Slide 4: Frequency of T and NK-cell lymphomas in Asia
Park S, Ko YH. Peripheral T cell lymphoma in Asia. Int J Hematol 2014;99:227-239. Reprinted with permission of the Japanese Society of Hematology.
Slide 29: Off-label use: 100mg of pembrolizumab, HK, Singapore, Korea
Republished with permission of the American Society of Hematology, from Kwong YL, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase. Blood. 2017;129(17):2437-2442; permission conveyed through Copyright Clearance Center, Inc.
Owen A. O’Connor presentation
Slide 12: Schematic of study design, patient disposition, and thrombocytopenia as a function of schedule & dose
Republished with permission of American Society of Hematology, from Amengual JE…O’Connor OA. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood 2018;131:397-407; permission conveyed through Copyright Clearance Center, Inc.
Slide 13: Summary of response rates across study population for patients treated with romidepsin and pralatrexate
Same as slide above.
Slide 14: Pharmacokinetic parameters for pralatrexate and romidepsin in the study population
Same as slide above.
Slide 15: PFS and OS as a function of treatment in study population
Same as slide above.
Slide 19: The combination of HoME and HDAC inhibitor synergistically produces apoptosis across panel of T-cell lymphomas: tCTCL H9
Marchi E . . . O’Connor OA.The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. Br J Haematol 2015; 171:215-226.
Slide 20: Supervised hierarchial clustering based on GEP
Same as slide above.
Slide 27: Panobinostat plus bortezomib in PTCL
Reprinted from Lancet Haematol, Tan D, et al. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. 2015; 2(8):e326-e333, with permission from Elsevier.
Pier Luigi Zinzani presentation
Slides 4, 11: New agents in T-cell lymphomas (2), Belinostat (2)
O’Connor OA, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 2015; 33: 2492-2499. Reprinted with permission. © 2015 American Society of Clinical Oncology. All rights reserved.
Slides 5, 8, 10, 12, 18, 20: Pralatrexate (1), Romidepsin (1), Belinostat (1), Brentuximab vedotin – Anaplastic large cell lymphoma (1), Brentuximab vedotin – CD30+ peripheral T-cell lymphoma (1), Off-label compounds in peripheral T-cell lymphomas
Reprinted from Cancer Treat Rev, volume 60, Broccoli A, Argnani L, Zinzani PL. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease, pp 120-129, © 2017, with permission from Elsevier.
Slides 6, 7: Pralatrexate (2) and Pralatrexate (3)
O’Connor OA, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol, 2011; 29: 1182-1189. Reprinted with permission. © 2011 American Society of Clinical Oncology. All rights reserved.
Slide 9: Romidepsin (2)
Coiffier B, et al. J Clin Oncol 2012; 30: 631-636. Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
Slides 13, 14: Brentuximab vedotin – Anaplastic large cell lymphoma (2), Brentulximab vedotin — Anaplastic large cell lymphoma (3)
Pro B, et al. J Clin Oncol 2012; 30: 2190-2196. Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
Slides 16, 17: Brentuximab vedotin – Anaplastic large cell lymphoma (5), Brentuximab vedotin – Anaplastic large cell lymphoma (6)
Broccoli A, et al. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica 2017; 102: 1931-1935. Obtained from the Haematologica Journal website http://www.haematologica.org
Slide 19: Brentuximab vedotin –CD30+ peripheral T-cell lymphomas (2)
Horwitz SM, et al. Blood 2014; 123: 3095-3100. Permission conveyed through Copyright Clearance Center, Inc.
Slide 21: Gemcitabine in peripheral T-cell lymphomas
Zinzani PL, et al. Ann Oncol 2010; 21: 860-863. European Society of Medical Oncology licensee.
Slide 23: Lenalidomide in T-cell lymphomas (2)
Reprinted from Morschhauser F, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 2013, with permission from Elsevier.
Slides 24, 25: Bendamustine in T-cell lymphomas (1), Bendamustine in T-cell lymphomas (2)
Damaj G, et al. J Clin Oncol 2012; 31: 104-110. Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Hemedicus, the supporter, or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Release Date: March 20, 2018
Expiration Date: March 19, 2019
Note: This activity is no longer available for credit
Agenda
New targeted agents for PTCL
(Duration: 20 minutes)
Pier Luigi Zinzani, MD, PhD
Bologna University
Institute of Hematology “Seragnoli”
Bologna, Italy
Recently approved therapies for PTCL in Asia:
What have we learned from the US experience?
(Duration: 18 minutes)
Won Seog Kim, MD, PhD
Samsung Medical Center
Seoul, Republic of Korea
Novel combination therapies:
Where are we now and where are we going?
(Duration: 23 minutes)
Owen A. O’Connor, MD, PhD
Columbia University Medical Center
The New York Presbyterian Hospital
New York, NY USA
Provided by:
Original activity supported by an educational grant from:
Spectrum Pharmaceuticals
Learning Objectives
At the conclusion of this educational activity, the healthcare team will be better able to:
- Discuss the treatment and management of peripheral T-cell lymphoma
- Appraise how U.S. T-cell lymphoma treatment experience can impact practice in Asia
- Summarize the importance of combination therapy in peripheral T-cell lymphoma
Target Audience
Hematologists, oncologists, and other clinicians and scientists with an interest in T-cell lymphoma
Statement of Need
Peripheral T-cell lymphomas (PTCL) are rare, heterogeneous and aggressive neoplasms that are associated with a poor prognosis. In addition, with current therapies, up to 70% of patients undergo relapse or develop refractory disease. Recent evidence has indicated an increase in the incidence of PTCLs and hence current challenges including pathobiology, clinical management, new drug testing as well as clinical trial accrual, need to be addressed. This activity will provide the healthcare team with the ideal foundation to facilitate progress in PTCL treatment and management.
Won Seog Kim, MD, PhD (Presenter)
Samsung Medical Center
Seoul, Republic of Korea
Disclosure: Consulting fees: Celltrion; Contracted research: Takeda; Kyowa-Kirin; J & J; Merck; Donga; Novartis; Celltrion
Owen A. O’Connor, MD, PhD (Presenter)
Columbia University Medical Center
The New York Presbyterian Hospital
New York, NY USA
Disclosure: Contracted research: Celgene; Merck; Spectrum; Agensys
Pier Luigi Zinzani, MD, PhD (Presenter)
Bologna University
Institute of Hematology “Seragnoli”
Bologna, Italy
Disclosure: Speakers Bureau: Janssen; Merck; Servier; Gilead; Verastem; BMS; Sandoz; Mundipharma
Permissions
Won Seog Kim presentation
Slide 4: Frequency of T and NK-cell lymphomas in Asia
Park S, Ko YH. Peripheral T cell lymphoma in Asia. Int J Hematol 2014;99:227-239. Reprinted with permission of the Japanese Society of Hematology.
Slide 29: Off-label use: 100mg of pembrolizumab, HK, Singapore, Korea
Republished with permission of the American Society of Hematology, from Kwong YL, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase. Blood. 2017;129(17):2437-2442; permission conveyed through Copyright Clearance Center, Inc.
Owen A. O’Connor presentation
Slide 12: Schematic of study design, patient disposition, and thrombocytopenia as a function of schedule & dose
Republished with permission of American Society of Hematology, from Amengual JE…O’Connor OA. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood 2018;131:397-407; permission conveyed through Copyright Clearance Center, Inc.
Slide 13: Summary of response rates across study population for patients treated with romidepsin and pralatrexate
Same as slide above.
Slide 14: Pharmacokinetic parameters for pralatrexate and romidepsin in the study population
Same as slide above.
Slide 15: PFS and OS as a function of treatment in study population
Same as slide above.
Slide 19: The combination of HoME and HDAC inhibitor synergistically produces apoptosis across panel of T-cell lymphomas: tCTCL H9
Marchi E . . . O’Connor OA.The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. Br J Haematol 2015; 171:215-226.
Slide 20: Supervised hierarchial clustering based on GEP
Same as slide above.
Slide 27: Panobinostat plus bortezomib in PTCL
Reprinted from Lancet Haematol, Tan D, et al. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. 2015; 2(8):e326-e333, with permission from Elsevier.
Pier Luigi Zinzani presentation
Slides 4, 11: New agents in T-cell lymphomas (2), Belinostat (2)
O’Connor OA, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 2015; 33: 2492-2499. Reprinted with permission. © 2015 American Society of Clinical Oncology. All rights reserved.
Slides 5, 8, 10, 12, 18, 20: Pralatrexate (1), Romidepsin (1), Belinostat (1), Brentuximab vedotin – Anaplastic large cell lymphoma (1), Brentuximab vedotin – CD30+ peripheral T-cell lymphoma (1), Off-label compounds in peripheral T-cell lymphomas
Reprinted from Cancer Treat Rev, volume 60, Broccoli A, Argnani L, Zinzani PL. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease, pp 120-129, © 2017, with permission from Elsevier.
Slides 6, 7: Pralatrexate (2) and Pralatrexate (3)
O’Connor OA, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol, 2011; 29: 1182-1189. Reprinted with permission. © 2011 American Society of Clinical Oncology. All rights reserved.
Slide 9: Romidepsin (2)
Coiffier B, et al. J Clin Oncol 2012; 30: 631-636. Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
Slides 13, 14: Brentuximab vedotin – Anaplastic large cell lymphoma (2), Brentulximab vedotin — Anaplastic large cell lymphoma (3)
Pro B, et al. J Clin Oncol 2012; 30: 2190-2196. Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
Slides 16, 17: Brentuximab vedotin – Anaplastic large cell lymphoma (5), Brentuximab vedotin – Anaplastic large cell lymphoma (6)
Broccoli A, et al. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica 2017; 102: 1931-1935. Obtained from the Haematologica Journal website http://www.haematologica.org
Slide 19: Brentuximab vedotin –CD30+ peripheral T-cell lymphomas (2)
Horwitz SM, et al. Blood 2014; 123: 3095-3100. Permission conveyed through Copyright Clearance Center, Inc.
Slide 21: Gemcitabine in peripheral T-cell lymphomas
Zinzani PL, et al. Ann Oncol 2010; 21: 860-863. European Society of Medical Oncology licensee.
Slide 23: Lenalidomide in T-cell lymphomas (2)
Reprinted from Morschhauser F, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 2013, with permission from Elsevier.
Slides 24, 25: Bendamustine in T-cell lymphomas (1), Bendamustine in T-cell lymphomas (2)
Damaj G, et al. J Clin Oncol 2012; 31: 104-110. Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Hemedicus, the supporter, or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Iron deficiency anemia: Disease heterogeneity and the rapid evolution of traditional diagnosis and treatment paradigms
Release Date: February 1, 2018
Expiration Date: January 31, 2019
Note: This activity is no longer available for credit
Agenda
Classification and Causes of Iron Deficiency and Iron Deficiency Anemia (duration 14:30)
Maureen M. Achebe, MD, MPH
Clinical Director, Non-Malignant Hematology Clinic
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Diagnostic Approaches to Iron Deficiency Anemia:
Conventional Tests or Newer Assessments? (duration 13:00)
Thomas DeLoughery, MD, MACP
Professor of Medicine
OHSU School of Medicine
Portland, OR
Treatment: From Oral Iron Supplementation to Intravenous Therapy
(duration 21:00)
Michael Auerbach, MD, FACP
Clinical Professor of Medicine
Georgetown University School of Medicine
Washington, DC
Provided by:
Original activity supported by an educational grant from: Luitpold Pharmaceuticals, Inc.
Learning Objectives
After completing the activity, clinicians will be better able to:
- Describe iron metabolism and the mechanism of iron deficiency and iron deficiency anemia
- Differentiate the causes of iron deficiency and iron deficiency anemia and confounding factors
- Evaluate the different approaches to diagnose iron deficiency and iron deficiency anemia
- Discuss the indications for intravenous iron therapy, the various formulations, and the benefits and risk of each
Target Audience
Hematologists, oncologists, and allied healthcare professionals who manage patients with iron deficiency anemia
Statement of Need
Iron deficiency (ID) and iron deficiency anemia (IDA) are common conditions worldwide, with 1.6 billion people in both developing and developed countries affected by these conditions, which can have serious consequences. Clinicians can readily diagnose ID and IDA in a healthy individual with a single cause of anemia. However, “explosive knowledge” of iron metabolism over the last 20 years has made it increasingly more difficult for them to determine the correct diagnosis and treatment [Camaschella, Blood Rev 2017]. This leaves clinicians uncertain as to the appropriate tests to order, how to interpret the results, what treatment to use, and at what dose. This activity is designed to clarify these issues and help the healthcare team provide optimal care for patients.
Disclosures
Maureen Achebe, MD (Presenter)
Consulting fees: Luitpold Pharmaceuticals, Inc., AMAG Pharmaceuticals, Inc., Syros Pharmaceuticals, Inc.
Michael Auerbach, MD (Course Director and Presenter)
Consulting fee: AMAG Pharmaceuticals, Inc., American Regent Luitpold, Pharmacosmos
Contracted research (Data management only): AMAG Pharmaceuticals, Pharmacosmos
Thomas DeLoughery, MD (Presenter)
No relevant financial relationships with a commercial interest.
Permissions
Maureen Achebe presentation
- Slide 14: Functional Iron Deficiency
Republished with permission of the American Society of Hematology, from Bruganara C, et al. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood 1993; 81(4):956-64; permission conveyed through Copyright Clearance Center, Inc.
- Slide 22: Prevalence of Anemia by Cr and GFR in a Pre-dialysis Population
McClellan W, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20(9):1501-10, reprinted by permission of the publisher (Taylor & Francis Ltd, http://www.tandfonline.com)
Michael Auerbach presentation
- Slide 9: Once vs Twice Daily Dosing
Reprinted from Lancet Haematol, Vol 4, No 11, Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials, e524-e533, © 2017, with permission from Elsevier.
- Slide 22: Iron Deficiency in Infancy Alters Neural Correlates of Recognition Memory at 10 Years: Key Study Results
Reprinted from J Pediatr, Vol 160, Congdon EL, Westerlund A, Algarin CR, et al. Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years, pp 1027-1033, © 2012, with permission from Elsevier.
Thomas DeLoughery presentation
- Slide 12: [No title]
From N Engl J Med, Lipschitz DA, Cook, JD, Finch CA, A clinical evaluation of serum ferritin as an index of iron stores, Vol 290, pages 1213-1216, © 1974 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
- Slide 15: Most Women Have Low Iron Stores
Reproduced with permission from JAMA, 1967, 199(12):897-900. Copyright© 1967 American Medical Association. All rights reserved
- Slide 16: Age and Ferritin
Reprinted from Am Heart J, Vol 140, Zacharski LR, Ornstein, DL, Woloshin S, et al. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data, pp 98-104, © 2000, with permission from Elsevier.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Hemedicus, the supporter, or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Release Date: February 1, 2018
Expiration Date: January 31, 2019
Note: This activity is no longer available for credit
Agenda
Classification and Causes of Iron Deficiency and Iron Deficiency Anemia (duration 14:30)
Maureen M. Achebe, MD, MPH
Clinical Director, Non-Malignant Hematology Clinic
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Diagnostic Approaches to Iron Deficiency Anemia:
Conventional Tests or Newer Assessments? (duration 13:00)
Thomas DeLoughery, MD, MACP
Professor of Medicine
OHSU School of Medicine
Portland, OR
Treatment: From Oral Iron Supplementation to Intravenous Therapy
(duration 21:00)
Michael Auerbach, MD, FACP
Clinical Professor of Medicine
Georgetown University School of Medicine
Washington, DC
Provided by:
Original activity supported by an educational grant from: Luitpold Pharmaceuticals, Inc.
Learning Objectives
After completing the activity, clinicians will be better able to:
- Describe iron metabolism and the mechanism of iron deficiency and iron deficiency anemia
- Differentiate the causes of iron deficiency and iron deficiency anemia and confounding factors
- Evaluate the different approaches to diagnose iron deficiency and iron deficiency anemia
- Discuss the indications for intravenous iron therapy, the various formulations, and the benefits and risk of each
Target Audience
Hematologists, oncologists, and allied healthcare professionals who manage patients with iron deficiency anemia
Statement of Need
Iron deficiency (ID) and iron deficiency anemia (IDA) are common conditions worldwide, with 1.6 billion people in both developing and developed countries affected by these conditions, which can have serious consequences. Clinicians can readily diagnose ID and IDA in a healthy individual with a single cause of anemia. However, “explosive knowledge” of iron metabolism over the last 20 years has made it increasingly more difficult for them to determine the correct diagnosis and treatment [Camaschella, Blood Rev 2017]. This leaves clinicians uncertain as to the appropriate tests to order, how to interpret the results, what treatment to use, and at what dose. This activity is designed to clarify these issues and help the healthcare team provide optimal care for patients.
Disclosures
Maureen Achebe, MD (Presenter)
Consulting fees: Luitpold Pharmaceuticals, Inc., AMAG Pharmaceuticals, Inc., Syros Pharmaceuticals, Inc.
Michael Auerbach, MD (Course Director and Presenter)
Consulting fee: AMAG Pharmaceuticals, Inc., American Regent Luitpold, Pharmacosmos
Contracted research (Data management only): AMAG Pharmaceuticals, Pharmacosmos
Thomas DeLoughery, MD (Presenter)
No relevant financial relationships with a commercial interest.
Permissions
Maureen Achebe presentation
- Slide 14: Functional Iron Deficiency
Republished with permission of the American Society of Hematology, from Bruganara C, et al. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood 1993; 81(4):956-64; permission conveyed through Copyright Clearance Center, Inc.
- Slide 22: Prevalence of Anemia by Cr and GFR in a Pre-dialysis Population
McClellan W, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20(9):1501-10, reprinted by permission of the publisher (Taylor & Francis Ltd, http://www.tandfonline.com)
Michael Auerbach presentation
- Slide 9: Once vs Twice Daily Dosing
Reprinted from Lancet Haematol, Vol 4, No 11, Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials, e524-e533, © 2017, with permission from Elsevier.
- Slide 22: Iron Deficiency in Infancy Alters Neural Correlates of Recognition Memory at 10 Years: Key Study Results
Reprinted from J Pediatr, Vol 160, Congdon EL, Westerlund A, Algarin CR, et al. Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years, pp 1027-1033, © 2012, with permission from Elsevier.
Thomas DeLoughery presentation
- Slide 12: [No title]
From N Engl J Med, Lipschitz DA, Cook, JD, Finch CA, A clinical evaluation of serum ferritin as an index of iron stores, Vol 290, pages 1213-1216, © 1974 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
- Slide 15: Most Women Have Low Iron Stores
Reproduced with permission from JAMA, 1967, 199(12):897-900. Copyright© 1967 American Medical Association. All rights reserved
- Slide 16: Age and Ferritin
Reprinted from Am Heart J, Vol 140, Zacharski LR, Ornstein, DL, Woloshin S, et al. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data, pp 98-104, © 2000, with permission from Elsevier.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Hemedicus, the supporter, or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Release Date: February 1, 2018
Expiration Date: January 31, 2019
Note: This activity is no longer available for credit
Agenda
Classification and Causes of Iron Deficiency and Iron Deficiency Anemia (duration 14:30)
Maureen M. Achebe, MD, MPH
Clinical Director, Non-Malignant Hematology Clinic
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Diagnostic Approaches to Iron Deficiency Anemia:
Conventional Tests or Newer Assessments? (duration 13:00)
Thomas DeLoughery, MD, MACP
Professor of Medicine
OHSU School of Medicine
Portland, OR
Treatment: From Oral Iron Supplementation to Intravenous Therapy
(duration 21:00)
Michael Auerbach, MD, FACP
Clinical Professor of Medicine
Georgetown University School of Medicine
Washington, DC
Provided by:
Original activity supported by an educational grant from: Luitpold Pharmaceuticals, Inc.
Learning Objectives
After completing the activity, clinicians will be better able to:
- Describe iron metabolism and the mechanism of iron deficiency and iron deficiency anemia
- Differentiate the causes of iron deficiency and iron deficiency anemia and confounding factors
- Evaluate the different approaches to diagnose iron deficiency and iron deficiency anemia
- Discuss the indications for intravenous iron therapy, the various formulations, and the benefits and risk of each
Target Audience
Hematologists, oncologists, and allied healthcare professionals who manage patients with iron deficiency anemia
Statement of Need
Iron deficiency (ID) and iron deficiency anemia (IDA) are common conditions worldwide, with 1.6 billion people in both developing and developed countries affected by these conditions, which can have serious consequences. Clinicians can readily diagnose ID and IDA in a healthy individual with a single cause of anemia. However, “explosive knowledge” of iron metabolism over the last 20 years has made it increasingly more difficult for them to determine the correct diagnosis and treatment [Camaschella, Blood Rev 2017]. This leaves clinicians uncertain as to the appropriate tests to order, how to interpret the results, what treatment to use, and at what dose. This activity is designed to clarify these issues and help the healthcare team provide optimal care for patients.
Disclosures
Maureen Achebe, MD (Presenter)
Consulting fees: Luitpold Pharmaceuticals, Inc., AMAG Pharmaceuticals, Inc., Syros Pharmaceuticals, Inc.
Michael Auerbach, MD (Course Director and Presenter)
Consulting fee: AMAG Pharmaceuticals, Inc., American Regent Luitpold, Pharmacosmos
Contracted research (Data management only): AMAG Pharmaceuticals, Pharmacosmos
Thomas DeLoughery, MD (Presenter)
No relevant financial relationships with a commercial interest.
Permissions
Maureen Achebe presentation
- Slide 14: Functional Iron Deficiency
Republished with permission of the American Society of Hematology, from Bruganara C, et al. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood 1993; 81(4):956-64; permission conveyed through Copyright Clearance Center, Inc.
- Slide 22: Prevalence of Anemia by Cr and GFR in a Pre-dialysis Population
McClellan W, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20(9):1501-10, reprinted by permission of the publisher (Taylor & Francis Ltd, http://www.tandfonline.com)
Michael Auerbach presentation
- Slide 9: Once vs Twice Daily Dosing
Reprinted from Lancet Haematol, Vol 4, No 11, Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials, e524-e533, © 2017, with permission from Elsevier.
- Slide 22: Iron Deficiency in Infancy Alters Neural Correlates of Recognition Memory at 10 Years: Key Study Results
Reprinted from J Pediatr, Vol 160, Congdon EL, Westerlund A, Algarin CR, et al. Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years, pp 1027-1033, © 2012, with permission from Elsevier.
Thomas DeLoughery presentation
- Slide 12: [No title]
From N Engl J Med, Lipschitz DA, Cook, JD, Finch CA, A clinical evaluation of serum ferritin as an index of iron stores, Vol 290, pages 1213-1216, © 1974 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
- Slide 15: Most Women Have Low Iron Stores
Reproduced with permission from JAMA, 1967, 199(12):897-900. Copyright© 1967 American Medical Association. All rights reserved
- Slide 16: Age and Ferritin
Reprinted from Am Heart J, Vol 140, Zacharski LR, Ornstein, DL, Woloshin S, et al. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data, pp 98-104, © 2000, with permission from Elsevier.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Hemedicus, the supporter, or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Clinical Endpoints in PTCL: The Road Less Traveled
Release Date: August 1, 2017
Expiration Date: July 31, 2018
Note: This activity is no longer available for credit.
Agenda
Developing New Strategic Goals in PTCL (duration 27:00)
Andrei R. Shustov, MD
University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle, WA, USA
PTCL as a Rare Disease: A Case of Overall Survival (duration 19:00)
Owen A. O’Connor, MD, PhD
Columbia University Medical Center
The New York Presbyterian Hospital
New York, NY, USA
Why Might Response Rates Differ Between the East and West? (duration 17:00)
Kensei Tobinai, MD, PhD
National Cancer Center Hospital
Tokyo, Japan
Provided by:
Original activity supported by an educational grant from:
Spectrum Pharmaceuticals
Learning Objectives
At the end of the activity, participants should be able to:
- Explain why progression-free survival is important when treating patients with PTCL
- Determine when overall survival is possible
- Describe the challenges of using matched control analysis in PTCL clinical trials
- Discuss why different response rates to therapy for PTCL may be seen in Asian patients versus North American or European patients and define the possible contributing factors
Target Audience
Hematologists, oncologists, and other clinicians and scientists with an interest in T-cell lymphoma
Statement of Need
This activity explores clinical endpoints in PTCL, the importance of choosing the appropriate ones and the possibility of achieving them. Global and regional differences in PTCL are also explored as they relate to response rates. The presentations highlight the challenges physicians face in treating PTCL patients and recent developments are discussed to help practitioners evaluate the utility of these endpoints in choosing appropriate treatments to improve outcomes in their patients with PTCL.
FACULTY
Faculty
Andrei R. Shustov, MD
Disclosures: Consulting fee: Celgene; BMS
Owen O’Connor, MD, PhD
Disclosures: Consulting fees: Mundipharma; Celgene; Contracted Research: Mundipharma; Spectrum; Celgene; Seattle Genetics; TG Therapeutics; ADCT; Trillium
Kensei Tobinai, MD, PhD
Disclosures: Honoraria: Eisai; HUYA Bioscience International; Janssen; Mundipharma; Takeda; Zenyaku Kogyo; Contracted research: Abbvie; Celgene; Chugai Pharma; Eisai; GlaxoSmithKline; Janssen; Kyowa Hakko Kirin; Mundipharma; Ono Pharmaceutical; SERVIER; Takeda
Permissions
Andrei Shustov presentation
- Slide 7: PTCL Prognosis Is Indicative of Diverse Biology
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 8: PTCL: Global Epidemiology
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 9: PTCL: USA Epidemiology (top half)
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 9: PTCL: USA Epidemiology (bottom half)
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slide 10: PTCL Prognosis: Histology x Race (USA)
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slide 12: PTCL Prognosis: Clinical Features (top right side)
- Reprinted with permission. © 2013 American Society of Clinical Oncology. All rights reserved.
- Slide 14: PTCL Prognosis: Molecular Classifiers (left side)
- Republished with permission of the American Society of Hematology, from Parilla Castellar ER, et al. Blood 2014;124:1473-1480
- Slide 14: PTCL Prognosis: Molecular Classifiers (right side)
- Republished with permission of the American Society of Hematology, from Iqbal J, et al. Blood 2014;123:2915-2923
- Slide 17: US Epidemiology of PTCL
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slides 18-19: Romidepsin in Relapsed/Refractory PTCL
- Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
- Slides 20-22, 25: Romidepsin in Elderly Patients
- Shustov A, et al. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leuk Lymphoma 2017 [Epub ahead of print]. Reprinted by permission of Taylor & Francis Ltd, http://www.tandfonline.com
- Slides 27-28: Belinostat in Relapsed/Refractory PTCL
- Reprinted with permission. © 2015 American Society of Clinical Oncology. All rights reserved.
Kensei Tobinai presentation
- Slide 7: Overall Survival of ATL Pts in JCOG 9801
- Reprinted with permission. © 2007 American Society of Clinical Oncology. All rights reserved.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Hemedicus, the supporter, or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Release Date: August 1, 2017
Expiration Date: July 31, 2018
Note: This activity is no longer available for credit.
Agenda
Developing New Strategic Goals in PTCL (duration 27:00)
Andrei R. Shustov, MD
University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle, WA, USA
PTCL as a Rare Disease: A Case of Overall Survival (duration 19:00)
Owen A. O’Connor, MD, PhD
Columbia University Medical Center
The New York Presbyterian Hospital
New York, NY, USA
Why Might Response Rates Differ Between the East and West? (duration 17:00)
Kensei Tobinai, MD, PhD
National Cancer Center Hospital
Tokyo, Japan
Provided by:
Original activity supported by an educational grant from:
Spectrum Pharmaceuticals
Learning Objectives
At the end of the activity, participants should be able to:
- Explain why progression-free survival is important when treating patients with PTCL
- Determine when overall survival is possible
- Describe the challenges of using matched control analysis in PTCL clinical trials
- Discuss why different response rates to therapy for PTCL may be seen in Asian patients versus North American or European patients and define the possible contributing factors
Target Audience
Hematologists, oncologists, and other clinicians and scientists with an interest in T-cell lymphoma
Statement of Need
This activity explores clinical endpoints in PTCL, the importance of choosing the appropriate ones and the possibility of achieving them. Global and regional differences in PTCL are also explored as they relate to response rates. The presentations highlight the challenges physicians face in treating PTCL patients and recent developments are discussed to help practitioners evaluate the utility of these endpoints in choosing appropriate treatments to improve outcomes in their patients with PTCL.
FACULTY
Faculty
Andrei R. Shustov, MD
Disclosures: Consulting fee: Celgene; BMS
Owen O’Connor, MD, PhD
Disclosures: Consulting fees: Mundipharma; Celgene; Contracted Research: Mundipharma; Spectrum; Celgene; Seattle Genetics; TG Therapeutics; ADCT; Trillium
Kensei Tobinai, MD, PhD
Disclosures: Honoraria: Eisai; HUYA Bioscience International; Janssen; Mundipharma; Takeda; Zenyaku Kogyo; Contracted research: Abbvie; Celgene; Chugai Pharma; Eisai; GlaxoSmithKline; Janssen; Kyowa Hakko Kirin; Mundipharma; Ono Pharmaceutical; SERVIER; Takeda
Permissions
Andrei Shustov presentation
- Slide 7: PTCL Prognosis Is Indicative of Diverse Biology
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 8: PTCL: Global Epidemiology
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 9: PTCL: USA Epidemiology (top half)
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 9: PTCL: USA Epidemiology (bottom half)
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slide 10: PTCL Prognosis: Histology x Race (USA)
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slide 12: PTCL Prognosis: Clinical Features (top right side)
- Reprinted with permission. © 2013 American Society of Clinical Oncology. All rights reserved.
- Slide 14: PTCL Prognosis: Molecular Classifiers (left side)
- Republished with permission of the American Society of Hematology, from Parilla Castellar ER, et al. Blood 2014;124:1473-1480
- Slide 14: PTCL Prognosis: Molecular Classifiers (right side)
- Republished with permission of the American Society of Hematology, from Iqbal J, et al. Blood 2014;123:2915-2923
- Slide 17: US Epidemiology of PTCL
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slides 18-19: Romidepsin in Relapsed/Refractory PTCL
- Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
- Slides 20-22, 25: Romidepsin in Elderly Patients
- Shustov A, et al. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leuk Lymphoma 2017 [Epub ahead of print]. Reprinted by permission of Taylor & Francis Ltd, http://www.tandfonline.com
- Slides 27-28: Belinostat in Relapsed/Refractory PTCL
- Reprinted with permission. © 2015 American Society of Clinical Oncology. All rights reserved.
Kensei Tobinai presentation
- Slide 7: Overall Survival of ATL Pts in JCOG 9801
- Reprinted with permission. © 2007 American Society of Clinical Oncology. All rights reserved.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Hemedicus, the supporter, or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Release Date: August 1, 2017
Expiration Date: July 31, 2018
Note: This activity is no longer available for credit.
Agenda
Developing New Strategic Goals in PTCL (duration 27:00)
Andrei R. Shustov, MD
University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle, WA, USA
PTCL as a Rare Disease: A Case of Overall Survival (duration 19:00)
Owen A. O’Connor, MD, PhD
Columbia University Medical Center
The New York Presbyterian Hospital
New York, NY, USA
Why Might Response Rates Differ Between the East and West? (duration 17:00)
Kensei Tobinai, MD, PhD
National Cancer Center Hospital
Tokyo, Japan
Provided by:
Original activity supported by an educational grant from:
Spectrum Pharmaceuticals
Learning Objectives
At the end of the activity, participants should be able to:
- Explain why progression-free survival is important when treating patients with PTCL
- Determine when overall survival is possible
- Describe the challenges of using matched control analysis in PTCL clinical trials
- Discuss why different response rates to therapy for PTCL may be seen in Asian patients versus North American or European patients and define the possible contributing factors
Target Audience
Hematologists, oncologists, and other clinicians and scientists with an interest in T-cell lymphoma
Statement of Need
This activity explores clinical endpoints in PTCL, the importance of choosing the appropriate ones and the possibility of achieving them. Global and regional differences in PTCL are also explored as they relate to response rates. The presentations highlight the challenges physicians face in treating PTCL patients and recent developments are discussed to help practitioners evaluate the utility of these endpoints in choosing appropriate treatments to improve outcomes in their patients with PTCL.
FACULTY
Faculty
Andrei R. Shustov, MD
Disclosures: Consulting fee: Celgene; BMS
Owen O’Connor, MD, PhD
Disclosures: Consulting fees: Mundipharma; Celgene; Contracted Research: Mundipharma; Spectrum; Celgene; Seattle Genetics; TG Therapeutics; ADCT; Trillium
Kensei Tobinai, MD, PhD
Disclosures: Honoraria: Eisai; HUYA Bioscience International; Janssen; Mundipharma; Takeda; Zenyaku Kogyo; Contracted research: Abbvie; Celgene; Chugai Pharma; Eisai; GlaxoSmithKline; Janssen; Kyowa Hakko Kirin; Mundipharma; Ono Pharmaceutical; SERVIER; Takeda
Permissions
Andrei Shustov presentation
- Slide 7: PTCL Prognosis Is Indicative of Diverse Biology
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 8: PTCL: Global Epidemiology
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 9: PTCL: USA Epidemiology (top half)
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 9: PTCL: USA Epidemiology (bottom half)
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slide 10: PTCL Prognosis: Histology x Race (USA)
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slide 12: PTCL Prognosis: Clinical Features (top right side)
- Reprinted with permission. © 2013 American Society of Clinical Oncology. All rights reserved.
- Slide 14: PTCL Prognosis: Molecular Classifiers (left side)
- Republished with permission of the American Society of Hematology, from Parilla Castellar ER, et al. Blood 2014;124:1473-1480
- Slide 14: PTCL Prognosis: Molecular Classifiers (right side)
- Republished with permission of the American Society of Hematology, from Iqbal J, et al. Blood 2014;123:2915-2923
- Slide 17: US Epidemiology of PTCL
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slides 18-19: Romidepsin in Relapsed/Refractory PTCL
- Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
- Slides 20-22, 25: Romidepsin in Elderly Patients
- Shustov A, et al. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leuk Lymphoma 2017 [Epub ahead of print]. Reprinted by permission of Taylor & Francis Ltd, http://www.tandfonline.com
- Slides 27-28: Belinostat in Relapsed/Refractory PTCL
- Reprinted with permission. © 2015 American Society of Clinical Oncology. All rights reserved.
Kensei Tobinai presentation
- Slide 7: Overall Survival of ATL Pts in JCOG 9801
- Reprinted with permission. © 2007 American Society of Clinical Oncology. All rights reserved.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Hemedicus, the supporter, or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Preventing Preterm Birth: The Most Important Challenge in Today’s Obstetrics
Vincenzo Berghella, MD
Professor
Division of Maternal-Fetal Medicine
Department of Obstetrics and Gynecology
Sidney Kimmel Medical College of Thomas
Jefferson University
Philadelphia, PA
Cynthia Gyamfi-Bannerman, MD, MSc
Ellen Jacobson Levine and Eugene Jacobson
Associate Professor of Women’s Health
in OBGYN
Department of Obstetrics and Gynecology
Division of Maternal-Fetal Medicine
Columbia University Medical Center
New York, NY
David L. Gandell, MD
Clinical Professor of Obstetrics
and Gynecology
Department of Obstetrics and Gynecology
Strong Memorial Hospital
University of Rochester School
of Medicine and Dentistry
Rochester, NY
Tracy A. Manuck, MD, MSCI
Assistant Professor
University of North Carolina
Department of Obstetrics and Gynecology
Division of Maternal Fetal Medicine
Medical Director, UNC Prematurity
Prevention Program
University of North Carolina-Chapel Hill
Chapel Hill, NC
Daniel O’Keeffe, MD
Executive Vice President
Society for Maternal-Fetal Medicine
Washington, DC
Ashley S. Roman, MD, MPH
Clinical Assistant Professor
Division of Maternal Fetal Medicine
Department of Obstetrics and Gynecology
Director, Division of Maternal Fetal Medicine
NYU School of Medicine
NYU Langone Medical Center,
New York, NY
Click here to read the supplement
To receive CME credit, please read the article and go to www.omniaeducation.com/obg2016 to complete the online evaluation.
Vincenzo Berghella, MD
Professor
Division of Maternal-Fetal Medicine
Department of Obstetrics and Gynecology
Sidney Kimmel Medical College of Thomas
Jefferson University
Philadelphia, PA
Cynthia Gyamfi-Bannerman, MD, MSc
Ellen Jacobson Levine and Eugene Jacobson
Associate Professor of Women’s Health
in OBGYN
Department of Obstetrics and Gynecology
Division of Maternal-Fetal Medicine
Columbia University Medical Center
New York, NY
David L. Gandell, MD
Clinical Professor of Obstetrics
and Gynecology
Department of Obstetrics and Gynecology
Strong Memorial Hospital
University of Rochester School
of Medicine and Dentistry
Rochester, NY
Tracy A. Manuck, MD, MSCI
Assistant Professor
University of North Carolina
Department of Obstetrics and Gynecology
Division of Maternal Fetal Medicine
Medical Director, UNC Prematurity
Prevention Program
University of North Carolina-Chapel Hill
Chapel Hill, NC
Daniel O’Keeffe, MD
Executive Vice President
Society for Maternal-Fetal Medicine
Washington, DC
Ashley S. Roman, MD, MPH
Clinical Assistant Professor
Division of Maternal Fetal Medicine
Department of Obstetrics and Gynecology
Director, Division of Maternal Fetal Medicine
NYU School of Medicine
NYU Langone Medical Center,
New York, NY
Click here to read the supplement
To receive CME credit, please read the article and go to www.omniaeducation.com/obg2016 to complete the online evaluation.
Vincenzo Berghella, MD
Professor
Division of Maternal-Fetal Medicine
Department of Obstetrics and Gynecology
Sidney Kimmel Medical College of Thomas
Jefferson University
Philadelphia, PA
Cynthia Gyamfi-Bannerman, MD, MSc
Ellen Jacobson Levine and Eugene Jacobson
Associate Professor of Women’s Health
in OBGYN
Department of Obstetrics and Gynecology
Division of Maternal-Fetal Medicine
Columbia University Medical Center
New York, NY
David L. Gandell, MD
Clinical Professor of Obstetrics
and Gynecology
Department of Obstetrics and Gynecology
Strong Memorial Hospital
University of Rochester School
of Medicine and Dentistry
Rochester, NY
Tracy A. Manuck, MD, MSCI
Assistant Professor
University of North Carolina
Department of Obstetrics and Gynecology
Division of Maternal Fetal Medicine
Medical Director, UNC Prematurity
Prevention Program
University of North Carolina-Chapel Hill
Chapel Hill, NC
Daniel O’Keeffe, MD
Executive Vice President
Society for Maternal-Fetal Medicine
Washington, DC
Ashley S. Roman, MD, MPH
Clinical Assistant Professor
Division of Maternal Fetal Medicine
Department of Obstetrics and Gynecology
Director, Division of Maternal Fetal Medicine
NYU School of Medicine
NYU Langone Medical Center,
New York, NY
Click here to read the supplement
To receive CME credit, please read the article and go to www.omniaeducation.com/obg2016 to complete the online evaluation.
Hot Topics in Primary Care
Click here to read the Full Supplement
Credit is awarded for successful completion of the online evaluations at the links below; these links may also be found within the supplement on the first page of each article.
CME CREDIT: "Individualizing Pharmacologic Management of Irritable Bowel Syndrome"
- To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to pceconsortium.org/ibs.
CME CREDIT: "Pharmacologic Approach to Obesity Management"
- To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to cme.iafp.com/ and find the article in the Post-Tests and Evaluation Only tab.
Click here to read the Full Supplement
Credit is awarded for successful completion of the online evaluations at the links below; these links may also be found within the supplement on the first page of each article.
CME CREDIT: "Individualizing Pharmacologic Management of Irritable Bowel Syndrome"
- To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to pceconsortium.org/ibs.
CME CREDIT: "Pharmacologic Approach to Obesity Management"
- To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to cme.iafp.com/ and find the article in the Post-Tests and Evaluation Only tab.
Click here to read the Full Supplement
Credit is awarded for successful completion of the online evaluations at the links below; these links may also be found within the supplement on the first page of each article.
CME CREDIT: "Individualizing Pharmacologic Management of Irritable Bowel Syndrome"
- To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to pceconsortium.org/ibs.
CME CREDIT: "Pharmacologic Approach to Obesity Management"
- To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to cme.iafp.com/ and find the article in the Post-Tests and Evaluation Only tab.
Health literacy and medication understanding among hospitalized adults
If you wish to receive credit for this activity, please refer to the website:
Accreditation and Designation Statement
Blackwell Futura Media Services designates this journal‐based CME activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Educational Objectives
Upon completion of this activity, participants will be better able to:
-
Assess the factors associated with reduced medication adherence.
-
Distinguish which components of medication understanding are assessed by the Medication Understanding Questionnaire.
This manuscript underwent peer review in line with the standards of editorial integrity and publication ethics maintained by Journal of Hospital Medicine. The peer reviewers have no relevant financial relationships. The peer review process for Journal of Hospital Medicine is single‐blinded. As such, the identities of the reviewers are not disclosed in line with the standard accepted practices of medical journal peer review.
Conflicts of interest have been identified and resolved in accordance with Blackwell Futura Media Services's Policy on Activity Disclosure and Conflict of Interest. The primary resolution method used was peer review and review by a non‐conflicted expert.
Instructions on Receiving Credit
For information on applicability and acceptance of CME credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within an hour; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to two years from initial publication.
Follow these steps to earn credit:
-
Log on to www.wileyblackwellcme.com
-
Read the target audience, learning objectives, and author disclosures.
-
Read the article in print or online format.
-
Reflect on the article.
-
Access the CME Exam, and choose the best answer to each question.
-
Complete the required evaluation component of the activity.
This activity will be available for CME credit for twelve months following its publication date. At that time, it will be reviewed and potentially updated and extended for an additional twelve months.
If you wish to receive credit for this activity, please refer to the website:
Accreditation and Designation Statement
Blackwell Futura Media Services designates this journal‐based CME activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Educational Objectives
Upon completion of this activity, participants will be better able to:
-
Assess the factors associated with reduced medication adherence.
-
Distinguish which components of medication understanding are assessed by the Medication Understanding Questionnaire.
This manuscript underwent peer review in line with the standards of editorial integrity and publication ethics maintained by Journal of Hospital Medicine. The peer reviewers have no relevant financial relationships. The peer review process for Journal of Hospital Medicine is single‐blinded. As such, the identities of the reviewers are not disclosed in line with the standard accepted practices of medical journal peer review.
Conflicts of interest have been identified and resolved in accordance with Blackwell Futura Media Services's Policy on Activity Disclosure and Conflict of Interest. The primary resolution method used was peer review and review by a non‐conflicted expert.
Instructions on Receiving Credit
For information on applicability and acceptance of CME credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within an hour; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to two years from initial publication.
Follow these steps to earn credit:
-
Log on to www.wileyblackwellcme.com
-
Read the target audience, learning objectives, and author disclosures.
-
Read the article in print or online format.
-
Reflect on the article.
-
Access the CME Exam, and choose the best answer to each question.
-
Complete the required evaluation component of the activity.
This activity will be available for CME credit for twelve months following its publication date. At that time, it will be reviewed and potentially updated and extended for an additional twelve months.
If you wish to receive credit for this activity, please refer to the website:
Accreditation and Designation Statement
Blackwell Futura Media Services designates this journal‐based CME activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Educational Objectives
Upon completion of this activity, participants will be better able to:
-
Assess the factors associated with reduced medication adherence.
-
Distinguish which components of medication understanding are assessed by the Medication Understanding Questionnaire.
This manuscript underwent peer review in line with the standards of editorial integrity and publication ethics maintained by Journal of Hospital Medicine. The peer reviewers have no relevant financial relationships. The peer review process for Journal of Hospital Medicine is single‐blinded. As such, the identities of the reviewers are not disclosed in line with the standard accepted practices of medical journal peer review.
Conflicts of interest have been identified and resolved in accordance with Blackwell Futura Media Services's Policy on Activity Disclosure and Conflict of Interest. The primary resolution method used was peer review and review by a non‐conflicted expert.
Instructions on Receiving Credit
For information on applicability and acceptance of CME credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within an hour; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to two years from initial publication.
Follow these steps to earn credit:
-
Log on to www.wileyblackwellcme.com
-
Read the target audience, learning objectives, and author disclosures.
-
Read the article in print or online format.
-
Reflect on the article.
-
Access the CME Exam, and choose the best answer to each question.
-
Complete the required evaluation component of the activity.
This activity will be available for CME credit for twelve months following its publication date. At that time, it will be reviewed and potentially updated and extended for an additional twelve months.